ERPR at Dr. Essa Lab

ERPR at Dr. Essa Lab

The Estrogen Receptor (ER) and Progesterone Receptor (PR) test, collectively known as the ERPR test, is a cornerstone of modern breast cancer diagnostics and personalized oncology. Performed at Dr. Essa Lab in Karachi, Pakistan, this highly specialized immunohistochemistry (IHC) assay evaluates the presence of hormone receptors on the surface and within the nuclei of breast cancer cells. Understanding the hormone receptor status of a tumor is not merely a diagnostic step; it is a critical prognostic and predictive tool that guides oncologists in designing targeted, life-saving therapeutic regimens. Dr. Essa Laboratory & Diagnostic Centre, with its legacy of clinical excellence since 1987, utilizes state-of-the-art automated staining platforms and high-specificity antibody clones to ensure the utmost accuracy in ERPR profiling.

Hormone receptors are specialized proteins found naturally in breast tissue cells. When estrogen and progesterone bind to these receptors, they signal the cells to grow and divide. In many breast cancers, these receptors are overexpressed, driving the rapid proliferation of malignant cells. By identifying whether a patient’s tumor is ER-positive, PR-positive, or hormone receptor-negative, the medical team can determine if the cancer is likely to respond to endocrine (hormone-blocking) therapies. These therapies, such as selective estrogen receptor modulators (SERMs) like tamoxifen or aromatase inhibitors (AIs) like anastrozole, letrozole, and exemestane, work by either blocking the receptors or lowering hormone levels in the body. Consequently, the ERPR at Dr. Essa Lab serves as an indispensable roadmap for breast cancer management, offering patients a highly tailored approach to their oncological care.

Clinical Procedure: What to Expect

Patient Preparation

Because the ERPR test is performed on a tissue specimen that has already been extracted from the body, there is no direct physical preparation required of the patient on the day of the laboratory analysis. However, the pre-analytical phase is absolutely critical to the accuracy of immunohistochemistry. Patients and referring clinicians must ensure the following preparation guidelines are met:

• Submission of Tissue Blocks: The patient or healthcare provider must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block along with the corresponding hematoxylin and eosin (H&E) stained slides from the primary biopsy or surgical resection.
• Clinical Documentation: A copy of the original histopathology report must accompany the sample. This report provides crucial context regarding the tumor grade, histological type, and specimen source.
• Fixation Guidelines (for clinicians): To prevent antigen degradation, the tissue must be fixed in 10% neutral buffered formalin within 1 hour of surgical removal (cold ischemia time < 60 minutes). The fixation duration should be between 6 and 72 hours. Deviations from these guidelines can lead to false-negative results.
• Information on Prior Therapy: It is essential to inform the laboratory if the patient has already undergone neoadjuvant chemotherapy or hormone therapy, as this can alter receptor expression.

During the Procedure

The laboratory phase of the ERPR test at Dr. Essa Lab is a highly controlled, multi-step immunohistochemical process conducted by specialized histotechnologists and evaluated by consultant pathologists:

• Sectioning: The paraffin block containing the tumor tissue is sliced into ultra-thin sections (typically 3 to 4 microns thick) using a high-precision microtome. These sections are then mounted onto positively charged glass slides to prevent tissue detachment during processing.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents (such as xylene) and graded alcohols to remove the paraffin wax and restore water to the tissue sections.
• Antigen Retrieval: The formalin fixation process creates cross-links that can mask target antigens. The slides undergo heat-induced epitope retrieval (HIER) using specialized buffer solutions in a temperature-controlled environment to expose the ER and PR proteins.
• Antibody Incubation: The tissue is incubated with highly specific primary monoclonal antibodies directed against the Estrogen Receptor (alpha subtype) and Progesterone Receptor proteins. Following this, secondary antibodies conjugated with detection enzymes are applied.
• Chromogen Visualization: A chromogenic substrate (typically diaminobenzidine, or DAB) is applied, which reacts with the enzyme complex to produce a visible brown precipitate within the nuclei of cells expressing ER and PR.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to color the non-reactive cell nuclei blue, providing a clear contrast. The slides are then dehydrated, cleared, and coverslipped for microscopic evaluation.
• Pathologist Interpretation: A consultant pathologist examines the slides under a high-resolution microscope, assessing the percentage of tumor nuclei showing positive brown staining and the intensity of the reaction.

When is a ERPR Performed?

Newly Diagnosed Invasive Breast Cancer

The ERPR test is universally recommended for every patient newly diagnosed with invasive breast carcinoma. Regardless of the patient’s age, menopausal status, tumor size, or lymph node involvement, establishing the hormone receptor status is the first step in clinical staging and treatment planning. It allows the multidisciplinary tumor board to categorize the cancer into specific molecular subtypes, such as Luminal A or Luminal B, which dictate the systemic therapy protocol.

Ductal Carcinoma In Situ (DCIS)

Physicians request ERPR testing on surgical specimens of Ductal Carcinoma In Situ (DCIS), which is a non-invasive, pre-cancerous condition. Identifying ER/PR expression in DCIS is highly valuable for determining whether adjuvant endocrine therapy (such as tamoxifen) should be recommended after breast-conserving surgery to reduce the risk of recurrence or the development of invasive cancer in either breast.

Recurrent or Metastatic Breast Cancer

In cases where breast cancer recurs locally or spreads to distant organs (metastasis), clinicians routinely order a repeat ERPR test on a biopsy of the recurrent or metastatic lesion. The biological characteristics of a tumor can evolve over time, a phenomenon known as receptor discordance. A tumor that was originally ER-positive may become ER-negative in its metastatic site, or vice versa, profoundly altering the subsequent therapeutic strategy.

Determining Eligibility for Endocrine Therapy

The primary clinical indication for ordering an ERPR test is to identify patients who will benefit from hormone receptor-targeted therapies. Patients whose tumors exhibit even low levels of ER or PR expression (as low as 1% of tumor cells) can derive significant clinical benefit from endocrine agents. Conversely, patients with hormone receptor-negative tumors are spared the side effects of these drugs, as they would derive no therapeutic benefit.

Prognostic Stratification

Oncologists utilize the ERPR status to understand the biological aggressiveness of the tumor. Generally, ER-positive and PR-positive breast cancers exhibit a more favorable short-to-medium-term prognosis, tend to be well-differentiated (lower grade), and show a slower rate of proliferation compared to hormone receptor-negative tumors. This prognostic information helps in counseling patients and determining the intensity of post-surgical surveillance.

What Does a ERPR Detect?

The ERPR test at Dr. Essa Lab evaluates a wide array of pathological and molecular parameters to provide a comprehensive diagnostic profile. The analysis detects and quantifies:

• Estrogen Receptor Alpha (ER-α) Expression: Detects the presence of estrogen receptor proteins specifically localized within the nuclei of the invasive tumor cells.
• Progesterone Receptor (PR) Expression: Detects the presence of progesterone receptor proteins, which serve as a functional downstream marker of an active estrogen receptor pathway.
• Percentage of Positive Tumor Nuclei: Quantifies the exact proportion of viable invasive cancer cells showing nuclear staining, ranging from 0% to 100%.
• Nuclear Staining Intensity: Categorizes the strength of the chromogenic signal as absent (0), weak (1+), moderate (2+), or strong (3+).
• Allred Score Calculation: A standardized scoring system that combines the proportion score (0-5) and intensity score (0-3) to yield a total score out of 8, helping to standardize clinical interpretation.
• Quick Score/H-Score: An alternative semi-quantitative scoring method that multiplies the percentage of positive cells by their staining intensity to provide a detailed molecular metric.
• Internal Positive Controls: Detects normal, non-neoplastic breast epithelial cells within the tissue section, which must show positive nuclear staining to validate the run’s technical accuracy.
• External Control Validation: Verifies the staining run against known positive and negative control tissue samples processed alongside the patient’s specimen.
• Cold Ischemia Time Adequacy: Indirectly assesses whether the specimen was placed in formalin promptly, as poor fixation leads to weak or absent staining in internal controls.
• Fixation Artifacts: Identifies areas of over-fixation or under-fixation (such as “edge effect” or poor central penetration) that could compromise diagnostic accuracy.
• Background Non-Specific Staining: Detects any cytoplasmic or stromal staining that must be excluded from the final nuclear score to avoid false-positive interpretations.
• Tumor Cell Viability: Evaluates whether the analyzed areas contain viable, well-preserved cancer cells rather than necrotic or degenerated tissue.
• Invasive vs. In Situ Components: Distinguishes receptor expression within the invasive front of the tumor from that within co-existing ductal carcinoma in situ (DCIS).
• Heterogeneity of Expression: Identifies distinct sub-populations of tumor cells with varying receptor density, which can influence treatment resistance.
• Decalcification Effects: Assesses if bone biopsy specimens have undergone decalcification processes that might have degraded the receptor proteins.
• Tissue Processing Quality: Evaluates the overall structural integrity of the tissue section, ensuring no folding, tearing, or chatter artifacts interfere with reading.
• Antibody Clone Specificity: Confirms the successful binding of specific diagnostic clones (such as SP1 for ER and PgR 636 for PR) to their respective epitopes.
• Nuclear Localization of Signal: Confirms that the brown chromogenic signal is strictly localized within the nucleus, as cytoplasmic staining is clinically non-significant.
• Inhibitory Factors: Detects the presence of exogenous substances or technical errors that may have inhibited the enzymatic chromogenic reaction.
• Pathologist Interpretation Metrics: Provides a qualitative and quantitative summary of the receptor status, classifying the tumor definitively as Positive, Low Positive, or Negative according to ASCO/CAP guidelines.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for oncology results can be an anxious time for patients and their families. The ERPR test involves intricate tissue processing, microtomy, immunohistochemical staining, and detailed microscopic evaluation by a consultant pathologist. Typically, the turnaround time for ERPR testing is 3 to 5 working days from the receipt of the tissue block at our main reference laboratory in Karachi.

Dr. Essa Lab offers a seamless digital reporting system. Once the consultant pathologist signs off on the report, patients receive an automated SMS notification. Reports can be accessed, viewed, and downloaded directly from the official Dr. Essa Lab website or mobile application. Physical copies of the reports, complete with high-resolution digital photomicrographs of the stained slides when applicable, can also be collected from any of our conveniently located collection centers across Karachi and other major cities.

ERPR Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Estrogen Receptor (ER) Status	Positive in normal breast epithelial cells (internal control)	Positive (≥1% nuclear staining) or Negative (<1% nuclear staining) in invasive tumor cells
Progesterone Receptor (PR) Status	Positive in normal breast epithelial cells (internal control)	Positive (≥1% nuclear staining) or Negative (<1% nuclear staining) in invasive tumor cells
Allred Scoring System	Not applicable to benign tissue (or score of 0 in completely negative tumors)	Scores ranging from 3 to 8, indicating varying degrees of positive receptor expression
Staining Intensity	Moderate to Strong (2+ to 3+) in normal lobules	Absent (0), Weak (1+), Moderate (2+), or Strong (3+) in malignant cells
Internal Control Validation	Normal adjacent breast ducts show strong nuclear staining	Absent staining in normal ducts, indicating pre-analytical tissue degradation or technical failure
Tumor Cell Viability	Highly viable tissue with preserved cellular architecture	Extensive necrosis, autolysis, or crush artifacts rendering the sample uninterpretable
Signal Localization	Strictly nuclear localization of the chromogen	Cytoplasmic or membranous staining without nuclear localization (considered clinically negative)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for ERPR?

• Experienced healthcare professionals: Our pathology department is led by highly qualified, board-certified histopathologists with extensive experience in oncological diagnostics.
• Patient-focused care: We prioritize patient comfort, clear communication, and compassionate service throughout the diagnostic journey.
• Quality diagnostic services: Dr. Essa Lab adheres to strict international quality control protocols, participating in external quality assurance programs.
• Professional reporting: Our reports are detailed, comprehensive, and structured in accordance with the latest international guidelines (ASCO/CAP).
• Modern diagnostic approach: We utilize fully automated immunohistochemistry staining platforms to minimize human error and ensure reproducibility.
• Comfortable environment: Our collection centers and diagnostic facilities are designed to provide a clean, safe, and welcoming experience.
• Convenient location: With an extensive network of branches across Karachi and Pakistan, accessing our services is easy and convenient.
• Commitment to accurate diagnosis: We understand the critical role of ERPR testing in cancer treatment and are dedicated to providing results you and your oncologist can trust.